Page 138 - 《中国药房》2024年19期

study of GC1008 （Fresolimumab） ：a human anti- solid tumors and non-small cell lung cancer[J]. BMC Can‐
transforming growth factor-beta （TGF-β） monoclonal an‐ cer，2023，23（1）：708-721.
tibody in patients with advanced malignant melanoma or [35] YAP T A，VIEITO M，BALDINI C，et al. First-in-human
renal cell carcinoma[J]. PLoS One，2014，9（3）：e90353. phase Ⅰ study of a next-generation，oral，TGF-β receptor
[24] ZHONG Z J，CARROLL K D，POLICARPIO D，et al. 1 inhibitor，LY3200882，in patients with advanced cancer
Anti-transforming growth factor beta receptor Ⅱ antibody [J]. Clin Cancer Res，2021，27（24）：6666-6676.
has therapeutic efficacy against primary tumor growth and [36] JUNG S Y，HWANG S，CLARKE J M，et al. Pharmacoki‐
metastasis through multieffects on cancer，stroma，and im‐ netic characteristics of vactosertib，a new activin receptor-
mune cells[J]. Clin Cancer Res，2010，16（4）：1191-1205. like kinase 5 inhibitor，in patients with advanced solid tu‐
[25] TOLCHER A W，BERLIN J D，COSAERT J，et al. A mors in a first-in-human phase 1 study[J]. Invest New
phase 1 study of anti-TGF-β receptor type-Ⅱ monoclonal Drugs，2020，38（3）：812-820.
antibody LY3022859 in patients with advanced solid tumors [37] LEE K W，PARK Y S，AHN J B，et al. Safety and anti-
[J]. Cancer Chemother Pharmacol，2017，79（4）：673-680. tumor activity of the transforming growth factor beta re‐
[26] MARTIN C J，DATTA A，LITTLEFIELD C，et al. Selec‐ ceptor Ⅰ kinase inhibitor，vactosertib，in combination
tive inhibition of TGF-β1 activation overcomes primary re‐ with pembrolizumab in patients with metastatic colorectal
sistance to checkpoint blockade therapy by altering tumor or gastric cancer[J]. J Immunother Cancer，2020，8（Suppl.
immune landscape[J]. Sci Transl Med，2020，12（536）： 3）：A358.
eaay8456. [38] JASCHINSKI F，ROTHHAMMER T，JACHIMCZAK P，
[27] YAP T A，BARVE M A，GAINOR J F，et al. First-in- et al. The antisense oligonucleotide trabedersen （AP
human phase 1 trial （DRAGON） of SRK-181，a potential 12009） for the targeted inhibition of TGF-β2[J]. Curr Pharm
first-in-class selective latent TGF-β1 inhibitor，alone or in Biotechnol，2011，12（12）：2203-2213.
combination with anti-PD-（L）1 treatment in patients with [39] BOGDAHN U，HAU P，STOCKHAMMER G，et al. Tar‐
advanced solid tumors[J]. J Clin Oncol，2021，39（Suppl. geted therapy for high-grade glioma with the TGF-β2 in‐
15）：TPS3146. hibitor trabedersen：results of a randomized and controlled
[28] BAUER T M，LIN C C，GREIL R，et al. Phase Ⅰb study phase Ⅱb study[J]. Neuro Oncol，2011，13（1）：132-142.
of the anti-TGF-β monoclonal antibody （MAb） NIS793 [40] GONZALEZ-JUNCA A，DRISCOLL K E，PELLICCIOTTA
combined with spartalizumab （PDR001），a PD-1 inhibi‐ I，et al. Autocrine TGF- β is a survival factor for mono‐
tor，in patients （pts） with advanced solid tumors[J]. J Clin cytes and drives immunosuppressive lineage commitment
Oncol，2021，39（Suppl. 15）：2509. [J]. Cancer Immunol Res，2019，7（2）：306-320.
[29] GRECO R，QU H J，QU H，et al. Pan-TGF-β inhibition [41] COURAU T，NEHAR-BELAID D，FLOREZ L，et al.
by SAR439459 relieves immunosuppression and im‐ TGF-β and VEGF cooperatively control the immunotole-
proves antitumor efficacy of PD-1 blockade[J]. Oncoim‐ rant tumor environment and the efficacy of cancer immu‐
munology，2020，9（1）：1811605. notherapies[J]. JCI Insight，2016，1（9）：e85974.
[30] MASCARENHASJ，MIGLIACCIO A R，KOSIOREK H， [42] BURVENICH I J G，GOH Y W，GUO N，et al. Radiolabel‐
et al. A phase Ⅰ b trial of AVID200，a TGF- β1/3 trap，in ling and preclinical characterization of 89Zr-Df-
patients with myelofibrosis[J]. Clin Cancer Res，2023，29 radiolabelled bispecific anti-PD-L1/TGF-βRⅡ fusion pro‐
（18）：3622-3632. tein bintrafusp alfa[J]. Eur J Nucl Med Mol Imag，2021，48
[31] YAP T A，LAKHANI N J，ARAUJO D V，et al. AVID200， （10）：3075-3088.
first-in-class TGF-beta 1 and 3 selective and potent inhibi‐ [43] CHAN M K，CHUNG J Y，TANG P C，et al. TGF-β sig‐
tor：safety and biomarker results of a phase Ⅰ mono‐ naling networks in the tumor microenvironment [J]. Can‐
therapy dose-escalation study in patients with advanced cer Lett，2022，550：215925.
solid tumors[J]. J Clin Oncol，2020，38（Suppl. 15）：3587. [44] GIACCONE G，BAZHENOVA L A，NEMUNAITIS J，
[32] FAIVRE S，SANTORO A，KELLEY R K，et al. Novel et al. A phase Ⅲ study of belagenpumatucel-L，an alloge‐
transforming growth factor beta receptor Ⅰ kinase inhibi‐ neic tumor cell vaccine，as maintenance therapy for non-
tor galunisertib （LY2157299） in advanced hepatocellular small cell lung cancer[J]. Eur J Cancer，2015，51（16）：
carcinoma[J]. Liver Int，2019，39（8）：1468-1477. 2321-2329.
[33] MELISI D，GARCIA-CARBONERO R，MACARULLA [45] WALTER A，ROCCONI R P，MONK B J，et al.
T，et al. TGF-β receptor inhibitor galunisertib is linked to Gemogenovatucel-T （Vigil） maintenance immunotherapy：
inflammation- and remodeling-related proteins in patients 3-year survival benefit in homologous recombination pro‐
with pancreatic cancer[J]. Cancer Chemother Pharmacol， ficient （HRP） ovarian cancer[J]. Gynecol Oncol，2021，
2019，83（5）：975-991. 163（3）：459-464.
[34] NADAL E，SALEH M，AIX S P，et al. A phase Ⅰb/Ⅱ （收稿日期：2024-03-15 修回日期：2024-08-12）
study of galunisertib in combination with nivolumab in （编辑：唐晓莲）

· 2448 · China Pharmacy 2024 Vol. 35 No. 19 中国药房 2024年第35卷第19期